Publication: Long COVID a perpetual threat even after COVID era? A case presentation
Files
Date
2022
Article Type
Case Report
Journal Title
Journal ISSN
ISSN 2822-1893 eISSN 2822-2016
Volume Title
Pages
Pages: 22 - 24
Publisher
Nepalese Respiratory Society
Abstract
Abstract:
Coronavirus disease 2019 (COVID-19) is a highly infectious disease. The acute phase of the disease has been focused upon and less importance is given to the long-term sequelae. A new term ‘long COVID’ is used to describe a diverse set of symptoms that persists for more than 12 weeks after a diagnosed COVID-19 infection with no alternative diagnosis. Predominant symptoms include persistent breathlessness, fatigue, cough, chest pain, palpitations, neurological and cognitive deficits, rashes, and gastrointestinal dysfunction. Risk factors for the development of long COVID are female gender, increased age, and increased BMI. Lung fibrosis is an important ailment in COVID survivors. Long COVID needs urgent attention for better understanding and specialized action plans to improve the quality of life in these patients and decrease their financial burden. Studies are warranted to investigate the early installation of antifibrotic agents in high-risk patients. Till we find better measures to counter long COVID, preventive measures and vaccination are the best available options. We are presenting here a case of long COVID who was admitted on multiple occasions for exacerbation of symptoms. He is now being managed on an outpatient basis.
Description
Asraf Hussain
Department of Internal Medicine, National Medical College, Birgunj, Nepal
Parwez Alam Ansari
Department of Internal Medicine, National Medical College, Birgunj, Nepal
Ajay Kumar Gupta
Department of Internal Medicine, National Medical College, Birgunj, Nepal
Omprakash Kushwaha
National Medical College, Birgunj, Nepal
Rupesh Shah
National Medical College, Birgunj, Nepal
Surendra Yadav
National Medical College, Birgunj, Nepal
Pratibha Kaushik
Dali University, Yunnan, China
Keywords
Long COVID, Vaccination, Lung fibrosis
Identifier
https://doi.org/10.3126/nrj.v1i1.45242